Literature DB >> 23600968

Predictors of survival and incidence of hepatoblastoma in the paediatric population.

Bassan J Allan1, Punam P Parikh, Sofia Diaz, Eduardo A Perez, Holly L Neville, Juan E Sola.   

Abstract

OBJECTIVES: This study evaluates current trends in incidence, clinical outcomes and factors predictive of survival in children with hepatoblastoma (HB).
METHODS: The Surveillance, Epidemiology and End Results (SEER) database was queried for the period 1973-2009 for all patients aged <20 years with HB.
RESULTS: A total of 606 patients were identified. The age-adjusted incidence was 0.13 patients per 100 000 in 2009. An annual percentage change of 2.18% (95% confidence interval (CI) 1.10-3.27; P < 0.05) was seen over the study period. Overall survival rates at 5, 10 and 20 years were 63%, 61% and 59%, respectively. Ten-year survival rates significantly improved in patients with resectable disease who underwent operative treatment in comparison with those with non-resectable HB (86% versus 39%; P < 0.0001). Multivariate analysis showed surgical treatment (hazard ratio (HR) = 0.23, 95% CI 0.17-0.31; P < 0.0001), Hispanic ethnicity (HR = 0.61, 95% CI 0.43-0.89; P = 0.01), local disease at presentation (HR = 0.43, 95% CI 0.29-0.63; P < 0.0001) and age < 5 years (HR = 0.63, 95% CI 0.41-0.95; P < 0.03) to be independent prognostic factors of survival.
CONCLUSIONS: The incidence of paediatric HB has increased over time. Hepatoblastoma is almost exclusively seen in children aged < 5 years. When HB presents after the age of 5 years, the prognosis is most unfavourable. Tumour extirpation markedly improves survival in paediatric patients with local disease.
© 2013 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2013        PMID: 23600968      PMCID: PMC3791112          DOI: 10.1111/hpb.12112

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  33 in total

Review 1.  Hepatic tumors in the pediatric age group: a distinctive clinicopathologic spectrum.

Authors:  L P Dehner
Journal:  Perspect Pediatr Pathol       Date:  1978

2.  Hepatocellular carcinoma in a noncirrhotic infant after prolonged parenteral nutrition.

Authors:  K Patterson; S P Kapur; R S Chandra
Journal:  J Pediatr       Date:  1985-05       Impact factor: 4.406

3.  Association between hepatoblastoma and very low birth weight: a trend or a chance?

Authors:  H Ikeda; S Matsuyama; M Tanimura
Journal:  J Pediatr       Date:  1997-04       Impact factor: 4.406

4.  Mesenchymal hamartoma of the liver: report of 30 cases and review of the literature.

Authors:  J T Stocker; K G Ishak
Journal:  Pediatr Pathol       Date:  1983 Jul-Sep

5.  Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group.

Authors:  J A Ortega; E C Douglass; J H Feusner; M Reynolds; J J Quinn; M J Finegold; J E Haas; D R King; W Liu-Mares; M G Sensel; M D Krailo
Journal:  J Clin Oncol       Date:  2000-07       Impact factor: 44.544

Review 6.  Large hepatic mesenchymal hamartoma leading to mid-trimester fetal demise.

Authors:  J-M Laberge; Y Patenaude; V Desilets; L Cartier; S Khalife; L Jutras; M-F Chen
Journal:  Fetal Diagn Ther       Date:  2005 Mar-Apr       Impact factor: 2.587

7.  Pediatric solid tumors and second malignancies: characteristics and survival outcomes.

Authors:  Vanitha Vasudevan; Michael C Cheung; Relin Yang; Ying Zhuge; Anne C Fischer; Leonidas G Koniaris; Juan E Sola
Journal:  J Surg Res       Date:  2009-06-21       Impact factor: 2.192

Review 8.  Neonatal liver tumours.

Authors:  Dietrich von Schweinitz
Journal:  Semin Neonatol       Date:  2003-10

9.  Mesenchymal hamartoma of the liver. A 35-year review.

Authors:  C A DeMaioribus; K P Lally; K Sim; H Isaacs; G H Mahour
Journal:  Arch Surg       Date:  1990-05

10.  Perinatal (congenital and neonatal) neoplasms: a report of 110 cases.

Authors:  H Isaacs
Journal:  Pediatr Pathol       Date:  1985
View more
  34 in total

1.  Development of the Serum α-Fetoprotein Reference Range in Patients with Beckwith-Wiedemann Spectrum.

Authors:  Kelly A Duffy; Jennifer L Cohen; Okan U Elci; Jennifer M Kalish
Journal:  J Pediatr       Date:  2019-06-22       Impact factor: 4.406

2.  The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival.

Authors:  Laura L Stafman; Mary G Waldrop; Adele P Williams; Jamie M Aye; Jerry E Stewart; Elizabeth Mroczek-Musulman; Karina J Yoon; Kimberly Whelan; Elizabeth A Beierle
Journal:  J Pediatr Surg       Date:  2019-02-28       Impact factor: 2.545

3.  Right trisegmentectomy after portal vein embolization in a high-risk toddler with hepatoblastoma.

Authors:  Nhatrang Le; Douglas C Rivard; Rebecca M Rentea; Michelle Manalang; Walter Andrews; Bartholomew Kane; Richard J Hendrickson
Journal:  Pediatr Surg Int       Date:  2018-03-29       Impact factor: 1.827

4.  Pediatric papillary thyroid carcinoma: outcomes and survival predictors in 2504 surgical patients.

Authors:  Samuel Golpanian; Eduardo A Perez; Jun Tashiro; John I Lew; Juan E Sola; Anthony R Hogan
Journal:  Pediatr Surg Int       Date:  2015-12-30       Impact factor: 1.827

5.  The utility of alpha-fetoprotein screening in Beckwith-Wiedemann syndrome.

Authors:  Kelly A Duffy; Matthew A Deardorff; Jennifer M Kalish
Journal:  Am J Med Genet A       Date:  2017-02-04       Impact factor: 2.802

6.  MicroRNA expression might predict prognosis of epithelial hepatoblastoma.

Authors:  Mónika Gyugos; Gábor Lendvai; István Kenessey; Krisztina Schlachter; Judit Halász; Péter Nagy; Miklós Garami; Zsuzsa Jakab; Zsuzsa Schaff; András Kiss
Journal:  Virchows Arch       Date:  2014-02-26       Impact factor: 4.064

7.  Minimally-invasive liver resection in pediatric patients: initial experience and outcomes.

Authors:  Michelle A Veenstra; Alan J Koffron
Journal:  HPB (Oxford)       Date:  2016-04-23       Impact factor: 3.647

8.  Survival and analysis of prognostic factors for hepatoblastoma: based on SEER database.

Authors:  Tie-Cheng Feng; Hong-Yan Zai; Wei Jiang; Qin Zhu; Bo Jiang; Lei Yao; Xin-Ying Li; Zhi-Ming Wang
Journal:  Ann Transl Med       Date:  2019-10

9.  Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.

Authors:  Penelope R Brock; Rudolf Maibach; Margaret Childs; Kaukab Rajput; Derek Roebuck; Michael J Sullivan; Véronique Laithier; Milind Ronghe; Patrizia Dall'Igna; Eiso Hiyama; Bénédicte Brichard; Jane Skeen; M Elena Mateos; Michael Capra; Arun A Rangaswami; Marc Ansari; Catherine Rechnitzer; Gareth J Veal; Anna Covezzoli; Laurence Brugières; Giorgio Perilongo; Piotr Czauderna; Bruce Morland; Edward A Neuwelt
Journal:  N Engl J Med       Date:  2018-06-21       Impact factor: 91.245

10.  Histological and immunohistochemical study of hepatoblastoma: correlation with tumour behaviour and survival.

Authors:  Kala Gnanasekaran Kiruthiga; Banumathi Ramakrishna; Soumitra Saha; Sudipta Sen
Journal:  J Gastrointest Oncol       Date:  2018-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.